Clinical Trials Browser

Carcinoma, Renal Cell × Tyrosine Kinase Inhibitors × Gastrointestinal × Clear all

NCT03890731 2024-04-02

A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed

Phase 2 Completed

6 enrolled 11 charts

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms